231 related articles for article (PubMed ID: 17495522)
1. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.
Koehl GE; Geissler EK; Iacobelli M; Frei C; Burger V; Haffner S; Holler E; Andreesen R; Schlitt HJ; Eissner G
Cancer Biol Ther; 2007 May; 6(5):686-90. PubMed ID: 17495522
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL.
Wang X; Pan B; Hashimoto Y; Ohkawara H; Xu K; Zeng L; Ikezoe T
Thromb Haemost; 2018 Jan; 118(1):161-173. PubMed ID: 29304536
[TBL] [Abstract][Full Text] [Related]
4. Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth.
Zhang E; Shi H; Yang L; Wu X; Wang Z
Oncol Rep; 2017 Jul; 38(1):359-367. PubMed ID: 28534996
[TBL] [Abstract][Full Text] [Related]
5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
6. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells.
Furuno A; Watari K; Nakamura M; Fukunaga Y; Jung JH; Ono M
Int J Oncol; 2011 Feb; 38(2):493-501. PubMed ID: 21132269
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
8. Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells.
Jeong A; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Bae H; Kim SH
Biol Pharm Bull; 2010; 33(6):945-50. PubMed ID: 20522957
[TBL] [Abstract][Full Text] [Related]
9. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
10. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
11. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1.
Lu N; Yang Y; You QD; Ling Y; Gao Y; Gu HY; Zhao L; Wang XT; Guo QL
Cancer Lett; 2007 Dec; 258(1):80-9. PubMed ID: 17920764
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism.
Brizzi MF; Battaglia E; Montrucchio G; Dentelli P; Del Sorbo L; Garbarino G; Pegoraro L; Camussi G
Circ Res; 1999 Apr; 84(7):785-96. PubMed ID: 10205146
[TBL] [Abstract][Full Text] [Related]
14. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
15. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
16. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
[TBL] [Abstract][Full Text] [Related]
17. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
Wang H; Zhang C; Ning Z; Xu L; Zhu X; Meng Z
Int J Oncol; 2016 Mar; 48(3):1229-41. PubMed ID: 26782953
[TBL] [Abstract][Full Text] [Related]
18. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
[TBL] [Abstract][Full Text] [Related]
19. 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.
Pang X; Zhang L; Lai L; Chen J; Wu Y; Yi Z; Zhang J; Qu W; Aggarwal BB; Liu M
Carcinogenesis; 2011 Jun; 32(6):904-12. PubMed ID: 21427164
[TBL] [Abstract][Full Text] [Related]
20. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
